Effects of Caffeine on Cerebral Blood Flow

Escola Superior de Tecnologia da Saúde de Coimbra

Status: Completed

Conditions: Cardiovascular System

Treatments: Other: Anhydrous caffeine (120mg); Other: Anhydrous caffeine (45mg); Other: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT05866848

CCBF

Details and patient eligibility

About

The goal of this clinical trial is to evaluate in clinically healthy young people if:

• after caffeine ingestion, there are variations in blood velocity of the middle cerebral arteries (VMCA),
• this variation is dependent on the administered dose.

Transcranial Doppler ultrasonography was used to record blood VMCA in three groups of 15 clinically healthy young adults each - no caffeine, low caffeine (45 mg) and high caffeine group (120 mg). Transcranial Doppler ultrasonography provided simultaneous bilateral VMCA measurements while subjects performed functional tests (hyperventilation and hypoventilation orders) and three cognitive activities (Test 1, short-term remembering, Test 2, solving a vocabulary problem, and Test 3, solving a math problem) each in 31-second tests with 1-minute rest between them. Participants were assessed before and 30 minutes after caffeine ingestion.

Full description

Were used in the study, Capsules dosed with 45mg and 120 mg of anhydrous caffeine and flour capsules as a placebo. In the preparation of the capsules, a semi-automatic capsulator No. 0 (Capsunorm® by Tecnyfarma®) were used, colorless hard gelatin capsules No. 0 by Acopharma® and anhydrous caffeine (Biochem®, C.A.S. 58-08-2).

Viasys Sonara transcranial Doppler unit and a 2 MHz probe were used to sample the middle cerebral artery at depths of 60 millimeters, using emission doppler pulsed performing spectral analysis in real time. Two probes (bilaterally) of 2MHz were placed at a depth between 55 and 60 mm, thus making it possible to analyse both middle cerebral arteries simultaneously.

Each participant was asked not to ingest caffeine and exercise vigorously for at least 12 hours before the assessment. In the case of smokers, they were also asked not to smoke for at least 2 hours before the evaluation. The laboratory had medium luminosity, silent and controlled temperature (23º/24ºC). To avoid inter-observer errors, all examinations were performed by the same investigator who was not aware of what dose was/had been administered to the participant.

Subjects were tested while seated in a reclining chair located in a dimly lit, sound-attenuated room and performed the activities with their eyes closed.

Enrollment: 45 patients

Sex: All

Ages: 18 to 30 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• clinically healthy young people

Exclusion criteria

• Individuals with hypertension, high cholesterol, diabetes, arrhythmias, carotid sinus syndrome, severe carotid stenosis and who were in an unstable clinical situation.

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

45 participants in 3 patient groups, including a placebo group

No caffeine

Placebo Comparator group

Description:

The control group took flour capsules.

Treatment:

Other: Placebo

Low caffeine

Experimental group

Description:

Group with relatively small amount of caffeine (45 mg) administered.

Treatment:

Other: Anhydrous caffeine (45mg)

High caffeine

Experimental group

Description:

Group with greater amount of caffeine (120 mg) administered.

Treatment:

Other: Anhydrous caffeine (120mg)